<div class="container">
  <div class="faq">
    <h1 class="faq_header">FAQ</h1>
    <p class="faq_text">Frequent Asked Questions - FAQ</p>
    <ul class="faq-list">
      <li class="faq-list_item" *ngFor="let data of FAQList; let i = index">
        <div class="d-flex align-items-center">
          <span class="faq-list_item-index">{{ i + 1 }}.</span>
          <h1 class="m-0 faq-list_item-question">
            {{ data.question }}
          </h1>
        </div>
        <div>
          <p class="faq-list_item-answer">
            {{ data.answer }}
          </p>
          <ul *ngIf="data.answerList.length > 1" class="faq-subList">
            <li class="faq-subList_item" *ngFor="let item of data.answerList">
              <span>{{ item }}</span>
            </li>
          </ul>
        </div>
        <hr />
      </li>
      <li class="faq-list_item">
        <div class="d-flex align-items-center">
          <span class="faq-list_item-index">13.</span>
          <h1 class="m-0 faq-list_item-question">
            What is Regulatory Affairs?
          </h1>
        </div>
        <div>
          <p class="faq-list_item-answer">
            <strong>Regulatory Affairs (RA),</strong> is a profession within
            regulated industries, such as pharmaceuticals and medical devices
            which ensures that companies comply with all of the regulations and
            laws pertaining to their business and develop and market safe and
            effective product.
          </p>
        </div>
        <hr />
      </li>
      <li class="faq-list_item">
        <div class="d-flex align-items-center">
          <span class="faq-list_item-index">14.</span>
          <h1 class="m-0 faq-list_item-question">What is Quality Assurance?</h1>
        </div>
        <div>
          <p class="faq-list_item-answer">
            <strong>Quality Assurance</strong>, or <strong>QA</strong> for
            short, refers to planned and systematic production processes that
            provide confidence in a product's suitability for its intended
            purpose (Wikipedia). For detailed definition refer to
            http://en.wikipedia.org/wiki/Quality_assurance
          </p>
        </div>
        <hr />
      </li>
      <li class="faq-list_item">
        <div class="d-flex align-items-center">
          <span class="faq-list_item-index">15.</span>
          <h1 class="m-0 faq-list_item-question">
            What are the steps of applying and getting medical device 510(k)
            clearance from US FDA?
          </h1>
        </div>
        <div>
          <p class="faq-list_item-answer">
            The process of obtaining 510(k) clearance from the U.S. Food and
            Drug Administration (FDA) for a medical device involves several
            steps. The 510(k) clearance is a premarket submission made to the
            FDA to demonstrate that the device to be marketed is at least as
            safe and effective as a legally marketed device that is not subject
            to premarket approval.
            <br />
            Here are the general steps for the 510(k) clearance process:
          </p>
          <ul class="faq-subList faq-subList-number">
            <li class="faq-subList_item">
              <span
                ><strong>Determine Device Classification:</strong> Identify the
                appropriate classification for your medical device. The FDA
                classifies devices into three classes (Class I, II, and III)
                based on their level of risk.</span
              >
            </li>
            <li class="faq-subList_item">
              <span
                ><strong>Pre-submission Interaction:</strong> Consider
                scheduling a pre-submission meeting with the FDA to discuss your
                device and gather feedback on the submission process. This is
                not mandatory but can be beneficial in clarifying regulatory
                expectations.</span
              >
            </li>
            <li class="faq-subList_item">
              <span
                ><strong>Identify a Predicate Device:</strong> Find a legally
                marketed device (predicate) that is similar to yours and has
                already received FDA clearance. This will be used as a reference
                for demonstrating substantial equivalence.</span
              >
            </li>
            <li class="faq-subList_item">
              <span
                ><strong>Prepare the 510(k) Submission:</strong> Compile all
                necessary documentation, including:
                <ul class="faq-subList-childList">
                  <li>Device description and specifications</li>
                  <li>Performance testing data</li>
                  <li>Biocompatibility information</li>
                  <li>Software documentation (if applicable)</li>
                  <li>Labeling and user manual</li>
                  <li>Risk analysis</li>
                  <li>Clinical data (if needed)</li>
                </ul>
              </span>
            </li>
            <li class="faq-subList_item">
              <span
                ><strong>Submit the 510(k) to the FDA:</strong> Prepare and
                submit the 510(k) application to the FDA through the Electronic
                Submission Gateway (ESG). Include the appropriate user fees with
                the submission.</span
              >
            </li>
            <li class="faq-subList_item">
              <span
                ><strong>FDA Review:</strong> The FDA will review the 510(k)
                submission. This may involve several rounds of questions and
                requests for additional information. The goal is to ensure that
                the device is substantially equivalent to the predicate device
                and meets regulatory requirements.</span
              >
            </li>
            <li class="faq-subList_item">
              <span
                ><strong>FDA Decision:</strong> Once the review is complete, the
                FDA will issue a decision. If the device is found to be
                substantially equivalent and meets all requirements, the FDA
                will issue a clearance letter.</span
              >
            </li>
            <li class="faq-subList_item">
              <span
                ><strong>Post-Market Requirements:</strong> After clearance, you
                must comply with post-market requirements, such as adverse event
                reporting, quality system regulations, and any special controls
                identified by the FDA.</span
              >
            </li>
          </ul>
          <p class="faq-list_item-answer">
            It's important to note that the specific requirements and timelines
            can vary based on the type and class of the device. Manufacturers
            are encouraged to refer to the FDA's guidance documents and
            communicate with the FDA throughout the process to ensure a smooth
            submission and review. Additionally, consulting with regulatory
            experts or consultants can be beneficial to navigate the
            complexities of the regulatory process.
          </p>
        </div>
        <hr />
      </li>
      <li class="faq-list_item">
        <div class="d-flex align-items-center">
          <span class="faq-list_item-index">16.</span>
          <h1 class="m-0 faq-list_item-question">
            What are the steps of applying and getting medical device PMA
            approval from US FDA?
          </h1>
        </div>
        <div>
          <p class="faq-list_item-answer">
            Obtaining Premarket Approval (PMA) from the U.S. Food and Drug
            Administration (FDA) for a medical device is a more rigorous process
            compared to the 510(k) clearance. PMA is required for high-risk
            devices and involves comprehensive scientific and regulatory review.
            Here are the general steps for applying and obtaining PMA approval:
          </p>
          <ul class="faq-subList faq-subList-number">
            <li class="faq-subList_item">
              <span
                ><strong>Determine Device Classification:</strong> Identify the
                appropriate classification for your medical device. PMA is
                typically required for Class III devices, which are considered
                high risk.</span
              >
            </li>
            <li class="faq-subList_item">
              <span
                ><strong>Pre-submission Interaction:</strong> Similar to the
                510(k) process, consider scheduling a pre-submission meeting
                with the FDA to discuss your device and gain insights into the
                submission process.</span
              >
            </li>
            <li class="faq-subList_item">
              <span
                ><strong>Prepare the PMA Application:</strong> Compile a
                comprehensive PMA application, including:
                <ul class="faq-subList-childList">
                  <li>Detailed device description and specifications</li>
                  <li>Preclinical testing data</li>
                  <li>Clinical trial data (if applicable)</li>
                  <li>Risk analysis and mitigation strategies</li>
                  <li>Biocompatibility information</li>
                  <li>
                    Manufacturing information and quality control measures
                  </li>
                  <li>Labeling and user manual</li>
                  <li>Proposed indications for use</li>
                </ul>
              </span>
            </li>
            <li class="faq-subList_item">
              <span
                ><strong>Submit the PMA Application to the FDA:</strong> Submit
                the PMA application to the FDA. PMA submissions are typically
                made through the FDA's Electronic Submission Gateway (ESG).
                Include the appropriate user fees with the submission.</span
              >
            </li>
            <li class="faq-subList_item">
              <span
                ><strong>FDA Filing Review:</strong> The FDA will conduct a
                filing review to ensure that the application is administratively
                complete. If the application is accepted for filing, the
                substantive review process begins.</span
              >
            </li>
            <li class="faq-subList_item">
              <span
                ><strong>FDA Substantive Review:</strong> The FDA will conduct a
                thorough scientific and regulatory review of the PMA
                application. This involves evaluating the safety and
                effectiveness of the device based on preclinical and clinical
                data. The FDA may request additional information or
                clarification during this process.</span
              >
            </li>
            <li class="faq-subList_item">
              <span
                ><strong>Advisory Panel Review (if applicable):</strong> For
                certain devices, the FDA may convene an advisory panel of
                external experts to provide additional input and recommendations
                on the device's safety and efficacy.</span
              >
            </li>
            <li class="faq-subList_item">
              <span
                ><strong>FDA Decision:</strong> Based on the review, the FDA
                will make a decision to either approve or deny the PMA. If
                approved, the FDA will issue a PMA approval letter.</span
              >
            </li>
            <li class="faq-subList_item">
              <span
                ><strong>Post-Approval Requirements:</strong> After PMA
                approval, manufacturers must adhere to post-approval
                requirements, including post-market surveillance, reporting of
                adverse events, and compliance with any special controls or
                conditions imposed by the FDA.</span
              >
            </li>
          </ul>
          <p class="faq-list_item-answer">
            It's important to note that the PMA process is resource-intensive
            and may require extensive clinical evidence. Engaging with the FDA
            early in the development process, conducting well-designed clinical
            trials, and seeking expert regulatory advice can help facilitate a
            smoother PMA submission and review process. Manufacturers are
            encouraged to refer to FDA guidance documents specific to PMA
            submissions for detailed information.
          </p>
        </div>
        <hr />
      </li>
      <li class="faq-list_item">
        <div class="d-flex align-items-center">
          <span class="faq-list_item-index">17.</span>
          <h1 class="m-0 faq-list_item-question">
            What are the steps of applying and getting medical device approval
            from Health Canada?
          </h1>
        </div>
        <div>
          <p class="faq-list_item-answer">
            In Canada, the regulatory authority for medical devices is Health
            Canada. The process for obtaining approval for a medical device in
            Canada involves several steps. Here is a general overview:
          </p>
          <ul class="faq-subList faq-subList-number">
            <li class="faq-subList_item">
              <span
                ><strong>Device Classification:</strong> Determine the
                appropriate classification for your medical device according to
                the risk-based classification system established by Health
                Canada (Class I, II, III, or IV).</span
              >
            </li>
            <li class="faq-subList_item">
              <span
                ><strong>Conduct a Pre-submission Meeting (Optional):</strong>
                While not mandatory, a pre-submission meeting with Health Canada
                can be helpful to discuss your device, the regulatory
                requirements, and to seek clarification on any issues before
                submitting the application.</span
              >
            </li>
            <li class="faq-subList_item">
              <span
                ><strong
                  >Prepare the Medical Device License (MDL) Application:</strong
                >
                Compile all necessary documentation for your Medical Device
                License (MDL) application. This typically includes:
                <ul class="faq-subList-childList">
                  <li>Device description and specifications</li>
                  <li>Device classification information</li>
                  <li>Quality management system (QMS) documentation</li>
                  <li>Risk analysis and management plan</li>
                  <li>Clinical evidence (if required)</li>
                  <li>Labeling and instructions for use</li>
                  <li>Summary of safety and effectiveness data</li>
                </ul>
              </span>
            </li>
            <li class="faq-subList_item">
              <span
                ><strong>Select the appropriate review pathway:</strong> Health
                Canada offers different pathways for the review of medical
                device applications, including standard review, priority review,
                and abbreviated review. Choose the pathway that best fits your
                device and intended use.</span
              >
            </li>
            <li class="faq-subList_item">
              <span
                ><strong>Submit the MDL Application:</strong> Submit the MDL
                application to Health Canada through the Medical Devices
                Directorate (MDD). Include the required fees with the
                submission.</span
              >
            </li>
            <li class="faq-subList_item">
              <span
                ><strong>MDL Application Review:</strong> Health Canada will
                review the application for completeness and conduct a thorough
                assessment of the safety, effectiveness, and quality of the
                medical device. This may involve requests for additional
                information or clarification.</span
              >
            </li>
            <li class="faq-subList_item">
              <span
                ><strong
                  >Quality Management System Audit (if applicable):</strong
                >
                For certain classes of devices, Health Canada may conduct an
                audit of the manufacturer's quality management system to ensure
                compliance with regulatory requirements.</span
              >
            </li>
            <li class="faq-subList_item">
              <span
                ><strong>Decision:</strong> Based on the review, Health Canada
                will make a decision to either issue a Medical Device License or
                refuse the application. If approved, a Medical Device License
                will be issued.</span
              >
            </li>
            <li class="faq-subList_item">
              <span
                ><strong>Post-Market Requirements:</strong> After receiving a
                Medical Device License, manufacturers must comply with
                post-market requirements, including adverse event reporting,
                ongoing monitoring, and compliance with any conditions imposed
                by Health Canada.</span
              >
            </li>
          </ul>
          <p class="faq-list_item-answer">
            It's important to note that the specific requirements and timelines
            can vary based on the class of the device and the review pathway
            chosen. Manufacturers are encouraged to refer to Health Canada's
            guidance documents and communicate with the regulatory authority
            throughout the process to ensure a smooth application and review
            process. Engaging with a regulatory consultant with expertise in
            Canadian medical device regulations may also be beneficial.
          </p>
        </div>
        <hr />
      </li>
      <li class="faq-list_item">
        <div class="d-flex align-items-center">
          <span class="faq-list_item-index">18.</span>
          <h1 class="m-0 faq-list_item-question">
            What are the steps of applying and getting medical device approval
            from Australia TGA?
          </h1>
        </div>
        <div>
          <p class="faq-list_item-answer">
            In Australia, the Therapeutic Goods Administration (TGA) is
            responsible for regulating medical devices. The process of obtaining
            approval for a medical device in Australia involves several steps.
            Here is a general overview:
          </p>
          <ul class="faq-subList faq-subList-number">
            <li class="faq-subList_item">
              <span
                ><strong>Device Classification:</strong> Determine the
                appropriate classification for your medical device based on the
                Australian regulatory framework. Medical devices are categorized
                into Classes I, IIa, IIb, III, and Active Implantable Medical
                Devices.</span
              >
            </li>
            <li class="faq-subList_item">
              <span
                ><strong>Conduct a Pre-submission Meeting (Optional):</strong>
                While not mandatory, you may consider arranging a pre-submission
                meeting with the TGA to discuss your device and seek
                clarification on regulatory requirements.</span
              >
            </li>
            <li class="faq-subList_item">
              <span
                ><strong>Prepare the Conformity Assessment Application:</strong>
                Compile all necessary documentation for your conformity
                assessment application. The type of application and required
                documentation may vary depending on the device class. Common
                elements include:
                <ul class="faq-subList-childList">
                  <li>Device description and specifications</li>
                  <li>Risk analysis and management plan</li>
                  <li>Quality management system (QMS) documentation</li>
                  <li>Clinical evidence (if required)</li>
                  <li>Labeling and Instructions for Use</li>
                  <li>Summary of safety and performance data</li>
                </ul>
              </span>
            </li>
            <li class="faq-subList_item">
              <span
                ><strong
                  >Select the appropriate conformity assessment route:</strong
                >
                The TGA offers different conformity assessment routes,
                including:
                <ul class="faq-subList-childList">
                  <li>
                    Class I devices: Self-certification or certification by a
                    Conformity Assessment Body (CAB).
                  </li>
                  <li>Class IIa, IIb, III devices: Certification by a CAB.</li>
                </ul>
              </span>
            </li>
            <li class="faq-subList_item">
              <span
                ><strong>Compile Technical File:</strong> For devices subject to
                certification by a Conformity Assessment Body, compile a
                technical file containing all relevant documentation and
                evidence of conformity.</span
              >
            </li>
            <li class="faq-subList_item">
              <span
                ><strong>Submit the Conformity Assessment Application:</strong>
                Submit the application to the TGA through the online TGA
                Business Services (TBS) portal. Include the required fees with
                the submission.</span
              >
            </li>
            <li class="faq-subList_item">
              <span
                ><strong>TGA Review:</strong> The TGA will review the
                application for completeness and conduct a detailed assessment
                of the device's safety, efficacy, and quality. This may involve
                requests for additional information or clarification.</span
              >
            </li>
            <li class="faq-subList_item">
              <span
                ><strong
                  >Conformity Assessment Body (CAB) Review (if
                  applicable):</strong
                >
                For devices subject to certification by a CAB, the CAB will
                review the technical file and issue a conformity assessment
                certificate if the device meets the requirements.</span
              >
            </li>
            <li class="faq-subList_item">
              <span
                ><strong>Decision:</strong> Based on the review, the TGA will
                make a decision to either issue a conformity assessment
                certificate or refuse the application. If approved, a conformity
                assessment certificate will be issued.</span
              >
            </li>
            <li class="faq-subList_item">
              <span
                ><strong>Post-Market Requirements:</strong> After obtaining
                approval, manufacturers must comply with post-market
                requirements, including adverse event reporting, ongoing
                monitoring, and compliance with any conditions imposed by the
                TGA.</span
              >
            </li>
          </ul>
          <p class="faq-list_item-answer">
            It's important to note that the specific requirements and timelines
            can vary based on the class of the device and the conformity
            assessment route chosen. Manufacturers are encouraged to refer to
            TGA guidance documents, interact with the TGA during the application
            process, and engage with regulatory consultants with expertise in
            Australian medical device regulations.
          </p>
        </div>
        <hr />
      </li>
      <li class="faq-list_item">
        <div class="d-flex align-items-center">
          <span class="faq-list_item-index">19.</span>
          <h1 class="m-0 faq-list_item-question">
            What are the steps of applying and getting medical device approval
            from Japan PMDA?
          </h1>
        </div>
        <div>
          <p class="faq-list_item-answer">
            In Japan, the Pharmaceuticals and Medical Devices Agency (PMDA) is
            responsible for the regulatory approval of medical devices. The
            process for obtaining approval for a medical device in Japan
            involves several steps. Here is a general overview:
          </p>
          <ul class="faq-subList faq-subList-number">
            <li class="faq-subList_item">
              <span
                ><strong>Determine Device Classification:</strong> Identify the
                appropriate classification for your medical device according to
                the Japanese regulatory system. Devices are categorized into
                Classes I, II, III, and IV based on the level of risk.</span
              >
            </li>
            <li class="faq-subList_item">
              <span
                ><strong>Conduct a Consultation Meeting (Optional):</strong>
                While not mandatory, manufacturers may choose to have a
                consultation meeting with the PMDA to discuss the regulatory
                requirements and seek guidance on the application process.</span
              >
            </li>
            <li class="faq-subList_item">
              <span
                ><strong
                  >Appoint a Marketing Authorization Holder (MAH):</strong
                >
                Foreign manufacturers are required to appoint a Japanese entity
                as the MAH, which will be responsible for the regulatory
                submissions and compliance in Japan.</span
              >
            </li>
            <li class="faq-subList_item">
              <span
                ><strong>Prepare the Application:</strong> Compile all necessary
                documentation for the marketing approval application. This
                typically includes:
                <ul class="faq-subList-childList">
                  <li>Device description and specifications</li>
                  <li>Risk analysis and management plan</li>
                  <li>Quality management system (QMS) documentation</li>
                  <li>Clinical data (if required)</li>
                  <li>Labeling and Instructions for Use</li>
                  <li>Summary of safety and effectiveness data</li>
                </ul>
              </span>
            </li>
            <li class="faq-subList_item">
              <span
                ><strong>Select the appropriate submission route:</strong>
                Choose the appropriate submission route based on the
                classification of your device. The submission routes include
                Pre-Market Certification (PMDA review) and Pre-Market Approval
                (PMDA review with expert panel evaluation).</span
              >
            </li>
            <li class="faq-subList_item">
              <span
                ><strong>Submit the Application to the PMDA:</strong> Submit the
                application to the PMDA. Include the required fees with the
                submission. The application can be submitted in Japanese or, if
                necessary, in English with a Japanese summary.</span
              >
            </li>
            <li class="faq-subList_item">
              <span
                ><strong>PMDA Review:</strong> The PMDA will review the
                application for completeness and conduct a detailed assessment
                of the device's safety, efficacy, and quality. This may involve
                requests for additional information or clarification.</span
              >
            </li>
            <li class="faq-subList_item">
              <span
                ><strong>Expert Panel Evaluation (if applicable):</strong> For
                certain high-risk devices, an expert panel may be convened to
                provide additional evaluation and recommendations.</span
              >
            </li>
            <li class="faq-subList_item">
              <span
                ><strong>Decision:</strong> Based on the review, the PMDA will
                make a decision to either approve or deny the marketing
                approval. If approved, a marketing approval certificate will be
                issued.</span
              >
            </li>
            <li class="faq-subList_item">
              <span
                ><strong>Post-Market Requirements:</strong> After obtaining
                marketing approval, manufacturers must comply with post-market
                requirements, including adverse event reporting, ongoing
                monitoring, and compliance with any conditions imposed by the
                PMDA.</span
              >
            </li>
          </ul>
          <p class="faq-list_item-answer">
            It's important to note that the specific requirements and timelines
            can vary based on the class of the device and the submission route
            chosen. Manufacturers are encouraged to refer to PMDA guidance
            documents, communicate with the PMDA during the application process,
            and may benefit from engaging with regulatory consultants familiar
            with Japanese medical device regulations.
          </p>
        </div>
        <hr />
      </li>
      <li class="faq-list_item">
        <div class="d-flex align-items-center">
          <span class="faq-list_item-index">20.</span>
          <h1 class="m-0 faq-list_item-question">
            What are the steps of applying and getting medical device approval
            from Brazil ANVISA?
          </h1>
        </div>
        <div>
          <p class="faq-list_item-answer">
            In Brazil, the regulatory authority responsible for the approval of
            medical devices is the National Health Surveillance Agency, or
            Agência Nacional de Vigilância Sanitária (ANVISA). The process for
            obtaining approval for a medical device in Brazil involves several
            steps. Here is a general overview:
          </p>
          <ul class="faq-subList faq-subList-number">
            <li class="faq-subList_item">
              <span
                ><strong>Determine Device Classification:</strong> Identify the
                appropriate classification for your medical device according to
                the Brazilian regulatory system. Medical devices are categorized
                into Classes I, II, III, and IV based on the level of
                risk.</span
              >
            </li>
            <li class="faq-subList_item">
              <span
                ><strong>Appoint a Local Registration Holder:</strong> Foreign
                manufacturers are required to appoint a Brazilian entity as the
                local Registration Holder, who will be responsible for
                regulatory submissions and compliance in Brazil.</span
              >
            </li>
            <li class="faq-subList_item">
              <span
                ><strong>Prepare the Technical Documentation:</strong> Compile
                all necessary documentation for the registration application.
                This typically includes:
                <ul class="faq-subList-childList">
                  <li>Device description and specifications</li>
                  <li>Risk analysis and management plan</li>
                  <li>Quality management system (QMS) documentation</li>
                  <li>Clinical data (if required)</li>
                  <li>Labeling and Instructions for Use</li>
                  <li>Summary of safety and performance data</li>
                </ul>
              </span>
            </li>
            <li class="faq-subList_item">
              <span
                ><strong
                  >Conduct Good Manufacturing Practices (GMP) Inspection (if
                  applicable):</strong
                >
                ANVISA may require a GMP inspection for certain classes of
                devices. Ensure that the manufacturing facilities comply with
                Brazilian regulations.</span
              >
            </li>
            <li class="faq-subList_item">
              <span
                ><strong>Submit the Registration Application to ANVISA:</strong>
                Submit the application to ANVISA. Include the required fees with
                the submission. The application can be submitted in
                Portuguese.</span
              >
            </li>
            <li class="faq-subList_item">
              <span
                ><strong>ANVISA Technical Review:</strong> ANVISA will conduct a
                technical review of the application, assessing the device's
                safety, efficacy, and quality. This may involve requests for
                additional information or clarification.</span
              >
            </li>
            <li class="faq-subList_item">
              <span
                ><strong>Clinical Evaluation (if applicable):</strong> For
                certain classes of devices, a clinical evaluation may be
                required. Provide the necessary clinical data to support the
                safety and performance of the device.</span
              >
            </li>
            <li class="faq-subList_item">
              <span
                ><strong>Decision:</strong> Based on the review, ANVISA will
                make a decision to either approve or deny the registration. If
                approved, a Certificate of Good Manufacturing Practices and
                Sanitary Surveillance (CBPF) will be issued.</span
              >
            </li>
            <li class="faq-subList_item">
              <span
                ><strong>Post-Market Requirements:</strong> After obtaining
                registration, manufacturers must comply with post-market
                requirements, including adverse event reporting, ongoing
                monitoring, and compliance with any conditions imposed by
                ANVISA.</span
              >
            </li>
          </ul>
          <p class="faq-list_item-answer">
            It's important to note that the specific requirements and timelines
            can vary based on the class of the device. Manufacturers are
            encouraged to refer to ANVISA guidance documents, communicate with
            ANVISA during the application process, and may benefit from engaging
            with regulatory consultants familiar with Brazilian medical device
            regulations.
          </p>
        </div>
        <hr />
      </li>
      <li class="faq-list_item">
        <div class="d-flex align-items-center">
          <span class="faq-list_item-index">21.</span>
          <h1 class="m-0 faq-list_item-question">
            What are the steps of applying and getting medical device approval
            from India?
          </h1>
        </div>
        <div>
          <p class="faq-list_item-answer">
            In India, the regulatory authority responsible for the approval of
            medical devices is the Central Drugs Standard Control Organization
            (CDSCO), under the Ministry of Health and Family Welfare. The
            process for obtaining approval for a medical device in India
            involves several steps. Here is a general overview:
          </p>
          <ul class="faq-subList faq-subList-number">
            <li class="faq-subList_item">
              <span
                ><strong>Determine Device Classification:</strong> Identify the
                appropriate classification for your medical device according to
                the Indian regulatory system. Medical devices are categorized
                into Classes A, B, and C, based on the level of risk.</span
              >
            </li>
            <li class="faq-subList_item">
              <span
                ><strong>Appoint an Indian Authorized Agent:</strong> Foreign
                manufacturers are required to appoint an Indian Authorized Agent
                who will act as the official representative and facilitate
                communication with the regulatory authorities.</span
              >
            </li>
            <li class="faq-subList_item">
              <span
                ><strong>Prepare the Technical Documentation:</strong> Compile
                all necessary documentation for the registration application.
                This typically includes:
                <ul class="faq-subList-childList">
                  <li>Device description and specifications</li>
                  <li>Risk analysis and management plan</li>
                  <li>Quality management system (QMS) documentation</li>
                  <li>Clinical data (if required)</li>
                  <li>Labeling and Instructions for Use</li>
                  <li>Summary of safety and performance data</li>
                </ul>
              </span>
            </li>
            <li class="faq-subList_item">
              <span
                ><strong
                  >Conduct Clinical Investigation (if applicable):</strong
                >
                For certain classes of devices, clinical investigations may be
                required to establish safety and efficacy. Obtain approval from
                the Institutional Ethics Committee (IEC) for clinical
                trials.</span
              >
            </li>
            <li class="faq-subList_item">
              <span
                ><strong>Conduct Regulatory Testing (if applicable):</strong>
                Some devices may require specific testing to ensure compliance
                with Indian standards. Ensure that testing is conducted in
                accredited laboratories.</span
              >
            </li>
            <li class="faq-subList_item">
              <span
                ><strong>Submit the Registration Application to CDSCO:</strong>
                Submit the application to CDSCO. Include the required fees with
                the submission. The application can be submitted in
                English.</span
              >
            </li>
            <li class="faq-subList_item">
              <span
                ><strong>CDSCO Review:</strong> CDSCO will review the
                application for completeness and conduct a detailed assessment
                of the device's safety, efficacy, and quality. This may involve
                requests for additional information or clarification.</span
              >
            </li>
            <li class="faq-subList_item">
              <span
                ><strong>Approval or Rejection:</strong> Based on the review,
                CDSCO will make a decision to either approve or reject the
                registration. If approved, a registration certificate will be
                issued.</span
              >
            </li>
            <li class="faq-subList_item">
              <span
                ><strong>Post-Market Requirements:</strong> After obtaining
                registration, manufacturers must comply with post-market
                requirements, including adverse event reporting, ongoing
                monitoring, and compliance with any conditions imposed by
                CDSCO.</span
              >
            </li>
          </ul>
          <p class="faq-list_item-answer">
            It's important to note that the specific requirements and timelines
            can vary based on the class of the device. Manufacturers are
            encouraged to refer to CDSCO guidance documents, communicate with
            CDSCO during the application process, and may benefit from engaging
            with regulatory consultants familiar with Indian medical device
            regulations.
          </p>
        </div>
        <hr />
      </li>
      <li class="faq-list_item">
        <div class="d-flex align-items-center">
          <span class="faq-list_item-index">22.</span>
          <h1 class="m-0 faq-list_item-question">
            What are the steps of applying and getting medical device approval
            from China NMPA?
          </h1>
        </div>
        <div>
          <p class="faq-list_item-answer">
            Obtaining approval for a medical device in China involves a process
            overseen by the National Medical Products Administration (NMPA). The
            approval process includes several steps. Please note that the
            regulatory landscape may evolve, and it's important to refer to the
            latest guidance from NMPA. Here is a general overview of the steps:
          </p>
          <ul class="faq-subList faq-subList-number">
            <li class="faq-subList_item">
              <span
                ><strong>Determine Device Classification:</strong> Identify the
                appropriate classification for your medical device according to
                the Chinese regulatory system. Medical devices are categorized
                into Classes I, II, III, and Class III devices are further
                divided into Class III-A and Class III-B based on increasing
                risk.</span
              >
            </li>
            <li class="faq-subList_item">
              <span
                ><strong>Establish a Local Entity:</strong> Foreign
                manufacturers need to establish a local entity in China, which
                will act as the license holder and be responsible for regulatory
                submissions.</span
              >
            </li>
            <li class="faq-subList_item">
              <span
                ><strong>Conduct Testing and Verification:</strong> Ensure that
                the medical device meets Chinese regulatory standards. This may
                involve testing and verification at NMPA-approved testing
                facilities.</span
              >
            </li>
            <li class="faq-subList_item">
              <span
                ><strong>Clinical Trial Approval (if applicable):</strong> For
                certain devices, clinical trials may be required to support
                safety and efficacy claims. Obtain approval from the National
                Medical Products Administration's Center for Medical Device
                Evaluation (NMPA-CDE) for clinical trials.</span
              >
            </li>
            <li class="faq-subList_item">
              <span
                ><strong>Compile Technical Documentation:</strong> Prepare all
                necessary technical documentation for the registration
                application. This typically includes:
                <ul class="faq-subList-childList">
                  <li>Device description and specifications</li>
                  <li>Risk analysis and management plan</li>
                  <li>Quality management system (QMS) documentation</li>
                  <li>Clinical trial data (if applicable)</li>
                  <li>Labeling and Instructions for Use</li>
                  <li>Summary of safety and performance data</li>
                </ul>
              </span>
            </li>
            <li class="faq-subList_item">
              <span
                ><strong>Submit the Application to NMPA-CDE:</strong> Submit the
                application to NMPA-CDE for the review and approval process.
                Include the required fees with the submission.</span
              >
            </li>
            <li class="faq-subList_item">
              <span
                ><strong>NMPA-CDE Review:</strong> NMPA-CDE will review the
                application for completeness and conduct a thorough evaluation
                of the device's safety, efficacy, and quality. This may involve
                requests for additional information or clarification.</span
              >
            </li>
            <li class="faq-subList_item">
              <span
                ><strong>On-site Inspection (if applicable):</strong> For
                certain high-risk devices, NMPA may conduct an on-site
                inspection of the manufacturing facilities to ensure compliance
                with regulations.</span
              >
            </li>
            <li class="faq-subList_item">
              <span
                ><strong>Decision:</strong> Based on the review, NMPA-CDE will
                make a decision to either approve or reject the registration. If
                approved, a registration certificate will be issued.</span
              >
            </li>
            <li class="faq-subList_item">
              <span
                ><strong>Post-Market Requirements:</strong> After obtaining
                registration, manufacturers must comply with post-market
                requirements, including adverse event reporting, ongoing
                monitoring, and compliance with any conditions imposed by
                NMPA.</span
              >
            </li>
          </ul>
          <p class="faq-list_item-answer">
            It's crucial to engage with regulatory experts familiar with the
            Chinese regulatory framework, stay informed about any updates or
            changes to the regulations, and follow the specific requirements
            outlined by NMPA for the device classification.
          </p>
        </div>
        <hr />
      </li>
      <li class="faq-list_item">
        <div class="d-flex align-items-center">
          <span class="faq-list_item-index">23.</span>
          <h1 class="m-0 faq-list_item-question">
            What is a Laboratory Developed Test (LDT)?
          </h1>
        </div>
        <div>
          <p class="faq-list_item-answer">
            A Laboratory Developed Test (LDT), also known as an in-house test or
            a homebrew test, refers to a diagnostic test that is developed,
            validated, and performed by a single laboratory for its own use.
            These tests are typically designed and implemented within a specific
            laboratory to meet the unique needs of that laboratory's patient
            population. LDTs are often created by clinical laboratories to
            diagnose or monitor diseases and conditions. br Key characteristics
            of Laboratory Developed Tests include:
          </p>
          <ul class="faq-subList faq-subList-number">
            <li class="faq-subList_item">
              <span
                ><strong>In-House Development:</strong> LDTs are created and
                developed within a specific laboratory rather than being
                commercially manufactured by an external entity. Laboratories
                may develop LDTs to address specific clinical needs that are not
                met by commercially available tests.</span
              >
            </li>
            <li class="faq-subList_item">
              <span
                ><strong>Customization:</strong>Laboratories have the
                flexibility to customize LDTs based on their specific
                requirements, patient population, and testing goals. This
                flexibility allows for adaptation to local needs and emerging
                scientific knowledge</span
              >
            </li>
            <li class="faq-subList_item">
              <span
                ><strong>Validation:</strong> Laboratories are responsible for
                validating the performance characteristics of LDTs, ensuring
                that they provide accurate and reliable results. This includes
                assessing sensitivity, specificity, precision, and other
                analytical and clinical performance parameters.</span
              >
            </li>
            <li class="faq-subList_item">
              <span
                ><strong>Regulatory Oversight:</strong> The regulation of LDTs
                in the United States has historically fallen under the oversight
                of the Centers for Medicare & Medicaid Services (CMS) under the
                Clinical Laboratory Improvement Amendments (CLIA). However, the
                regulatory landscape has been evolving, and there have been
                discussions about increased oversight by the U.S. Food and Drug
                Administration (FDA).</span
              >
            </li>
          </ul>
          <p class="faq-list_item-answer">
            It's important to note that the regulation of LDTs has been a topic
            of discussion and change. Traditionally, LDTs have been considered
            to be under the purview of clinical laboratories and regulated by
            CLIA. However, in recent years, there have been efforts to increase
            the regulatory oversight of LDTs, with proposals for increased FDA
            involvement.
          </p>
        </div>
        <hr />
      </li>
      <li class="faq-list_item">
        <div class="d-flex align-items-center">
          <span class="faq-list_item-index">24.</span>
          <h1 class="m-0 faq-list_item-question">
            What is the regulations Laboratory Developed Test (LDT) need to
            comply in USA?
          </h1>
        </div>
        <div>
          <p class="faq-list_item-answer">
            As of my last knowledge update in January 2022, the regulatory
            landscape for Laboratory Developed Tests (LDTs) in the United States
            was evolving. Traditionally, LDTs had been regulated under the
            Clinical Laboratory Improvement Amendments (CLIA) program
            administered by the Centers for Medicare & Medicaid Services (CMS).
            However, discussions and proposals for increased regulatory
            oversight by the U.S. Food and Drug Administration (FDA) were
            ongoing. Here are key aspects of the regulatory framework for LDTs
            in the U.S.:
          </p>
          <ul class="faq-subList faq-subList-number">
            <li class="faq-subList_item">
              <span
                ><strong
                  >Clinical Laboratory Improvement Amendments (CLIA):</strong
                >CLIA is a federal regulatory framework that establishes quality
                standards for laboratory testing to ensure the accuracy,
                reliability, and timeliness of patient test results.
                Laboratories, including those performing LDTs, must comply with
                CLIA requirements for personnel qualifications, quality control,
                proficiency testing, and other aspects of laboratory
                operations.</span
              >
            </li>
            <li class="faq-subList_item">
              <span
                ><strong>U.S. Food and Drug Administration (FDA):</strong>
                Historically, the FDA exercised enforcement discretion and did
                not actively regulate most LDTs, considering them to be the
                responsibility of CLIA. However, the FDA's approach has been
                evolving, with proposals to increase FDA oversight of LDTs. The
                FDA issued a draft guidance in 2014 outlining a risk-based
                approach to the regulation of LDTs, but this guidance has not
                been finalized as of the last update.</span
              >
            </li>
            <li class="faq-subList_item">
              <span
                ><strong>Proposed FDA Oversight:</strong> The FDA's proposed
                oversight would involve a risk-based classification system for
                LDTs, with higher-risk tests subject to more stringent
                regulation. The proposed framework includes pre-market review,
                quality system requirements, and adverse event reporting for
                certain LDTs. However, the specifics of this oversight and its
                implementation were still under consideration.</span
              >
            </li>
            <li class="faq-subList_item">
              <span
                ><strong>Compliance with Other Regulations:</strong> In addition
                to CLIA and potential FDA oversight, laboratories developing and
                performing LDTs may need to consider other regulations and
                standards, such as those related to privacy and data security
                (e.g., the Health Insurance Portability and Accountability Act -
                HIPAA).</span
              >
            </li>
          </ul>
          <p class="faq-list_item-answer">
            Since the regulatory landscape can change, it's important to check
            for the latest updates and guidance from regulatory authorities. As
            of my last update in January 2022, the status of FDA oversight for
            LDTs was still evolving. Laboratories and manufacturers of LDTs
            should monitor developments in regulatory policy and consult with
            regulatory experts to ensure compliance with the most current
            requirements.
          </p>
        </div>
        <hr />
      </li>
      <li class="faq-list_item">
        <div class="d-flex align-items-center">
          <span class="faq-list_item-index">25.</span>
          <h1 class="m-0 faq-list_item-question">
            What are the steps required to convert Laboratory Developed Test
            (LDT) to In Vitro Diagnostic Test (IVD) by US FDA?
          </h1>
        </div>
        <div>
          <p class="faq-list_item-answer">
            he regulatory landscape for Laboratory Developed Tests (LDTs) in the
            United States is evolving, and discussions were ongoing regarding
            increased oversight by the U.S. Food and Drug Administration (FDA).
            It's essential to note that regulatory information may change, and
            you should refer to the most recent guidance and regulations from
            the FDA for the latest information.
            <br />
            If there have been changes or updates since my last knowledge
            update, the steps for converting an LDT to an In Vitro Diagnostic
            (IVD) test under FDA oversight might include the following:
          </p>
          <ul class="faq-subList faq-subList-number">
            <li class="faq-subList_item">
              <span
                ><strong>Determine Applicability of FDA Oversight:</strong>
                <ul class="faq-subList-childList">
                  <li>
                    Assess whether the LDT falls under the FDA's jurisdiction
                    for regulation. The FDA has proposed a risk-based approach,
                    where higher-risk LDTs would be subject to more stringent
                    regulation.
                  </li>
                </ul>
              </span>
            </li>
            <li class="faq-subList_item">
              <span
                ><strong>Consult FDA Guidance Documents:</strong>
                <ul class="faq-subList-childList">
                  <li>
                    Review any guidance documents issued by the FDA related to
                    the regulation of LDTs and IVDs. The FDA may provide
                    specific guidance on the steps to transition an LDT to an
                    FDA-regulated IVD.
                  </li>
                </ul>
              </span>
            </li>
            <li class="faq-subList_item">
              <span
                ><strong
                  >Submit a Pre-Submission or Pre-Market Notification
                  (510(k)):</strong
                >
                <ul class="faq-subList-childList">
                  <li>
                    Prepare and submit a pre-submission or pre-market
                    notification (510(k)) to the FDA, including detailed
                    information about the test, its analytical and clinical
                    performance, and data supporting its safety and efficacy.
                  </li>
                </ul>
              </span>
            </li>
            <li class="faq-subList_item">
              <span
                ><strong>Quality System Requirements:</strong>
                <ul class="faq-subList-childList">
                  <li>
                    Implement a quality management system (QMS) that complies
                    with FDA regulations, such as the Quality System Regulation
                    (QSR) for medical devices. This may involve establishing
                    procedures for design control, risk management, and other
                    aspects of product development and manufacturing.
                  </li>
                </ul>
              </span>
            </li>
            <li class="faq-subList_item">
              <span
                ><strong>Performance Data:</strong>
                <ul class="faq-subList-childList">
                  <li>
                    Provide comprehensive performance data demonstrating the
                    accuracy, precision, and clinical performance of the IVD,
                    including analytical and clinical validation studies.
                  </li>
                </ul>
              </span>
            </li>
            <li class="faq-subList_item">
              <span
                ><strong>Labeling and Instructions for Use:</strong>
                <ul class="faq-subList-childList">
                  <li>
                    Prepare labeling and instructions for use that comply with
                    FDA requirements, including clear and accurate information
                    for healthcare professionals and end-users.
                  </li>
                </ul>
              </span>
            </li>
            <li class="faq-subList_item">
              <span
                ><strong>Establish Good Manufacturing Practices (GMP):</strong>
                <ul class="faq-subList-childList">
                  <li>
                    Implement good manufacturing practices (GMP) to ensure the
                    quality and consistency of the manufacturing process,
                    adhering to specific standards outlined in FDA regulations.
                  </li>
                </ul>
              </span>
            </li>
            <li class="faq-subList_item">
              <span
                ><strong>Adverse Event Reporting:</strong>
                <ul class="faq-subList-childList">
                  <li>
                    Develop procedures for adverse event reporting to comply
                    with FDA requirements, including reporting adverse events
                    related to their devices.
                  </li>
                </ul>
              </span>
            </li>
            <li class="faq-subList_item">
              <span
                ><strong>Engage with FDA:</strong>
                <ul class="faq-subList-childList">
                  <li>
                    Communicate with the FDA throughout the process, responding
                    to requests for additional information, participating in
                    meetings, and addressing concerns raised during the review
                    process.
                  </li>
                </ul>
              </span>
            </li>
          </ul>
          <p class="faq-list_item-answer">
            Since the regulatory landscape can change, it's important to check
            for the latest updates and guidance from regulatory authorities. As
            of my last update in January 2022, the status of FDA oversight for
            LDTs was still evolving. Laboratories and manufacturers of LDTs
            should monitor developments in regulatory policy and consult with
            regulatory experts to ensure compliance with the most current
            requirements.
          </p>
        </div>
        <hr />
      </li>
      <li class="faq-list_item">
        <div class="d-flex align-items-center">
          <span class="faq-list_item-index">26.</span>
          <h1 class="m-0 faq-list_item-question">
            What are the key take aways from FDA’s proposed rule to regulate
            Laboratory Developed Tests (LDTs)?
          </h1>
        </div>
        <div>
          <p class="faq-list_item-question pl-48px">
            Timeline for Phaseout Policy
          </p>
          <p class="faq-list_item-answer">
            The phaseout policy for all in-scope tests would consist of five
            stages, with each stage marking the end of FDA’s general enforcement
            discretion policy for different regulatory requirements. The five
            stages each begin at a certain time “after FDA publishes a final
            phaseout policy,” which is intended to be published in the preamble
            to the final rule, as follows:
          </p>
          <ul class="faq-subList faq-subList-number">
            <li class="faq-subList_item">
              <span>
                Medical device reporting (MDR) (21 CFR Part 803) and corrections
                and removal reporting (21 CFR Part 806) – 1 year after final
                phaseout policy published.
              </span>
            </li>
            <li class="faq-subList_item">
              <span>
                Registration and listing (21 CFR Part 807), labeling (21 CFR
                Parts 801 and 809, subpart B), and investigational use
                requirements (21 CFR Part 812) – 2 years after final phaseout
                policy published.
              </span>
            </li>
            <li class="faq-subList_item">
              <span>
                Quality system (QS) requirements (21 CFR Part 820) – 3 years
                after final phaseout policy published. For traditional LDTs
                (designed, manufactured, and performed within the same
                CLIA-certified, high-complexity laboratory), the applicable QS
                requirements include design controls (21 CFR 820.30), purchasing
                controls (21 CFR 820.50), acceptance activities (21 CFR 820.80
                and 21 CFR 820.86), corrective and preventative actions (21 CFR
                820.100), and records (21 CFR Part 820, subpart M).
              </span>
            </li>
            <li class="faq-subList_item">
              <span>
                Submission of premarket approval (PMA) applications for
                high-risk tests (i.e., class III devices) – 3.5 years after
                final phaseout policy published, but no earlier than October 1,
                2027. LDTs generally could continue to be offered as long as a
                PMA is under review.
              </span>
            </li>
            <li class="faq-subList_item">
              <span>
                Submission of 510(k) premarket notifications and de novo
                requests for moderate- and low-risk tests (i.e., non-exempt
                class I and II devices) – 4 years after final phaseout policy
                published, but no earlier than April 1, 2028. LDTs generally
                could continue to be offered as long as a premarket submission
                is under review.
              </span>
            </li>
          </ul>
        </div>
        <hr />
      </li>
      <li class="faq-list_item">
        <div class="d-flex align-items-center">
          <span class="faq-list_item-index">27.</span>
          <h1 class="m-0 faq-list_item-question">
            What articles of EU IVDR 746/2017 regulations and ISO 15189
            standards do Laboratory Developed Test (LDT) need to comply?
          </h1>
        </div>
        <div>
          <p class="faq-list_item-answer">
            Placing on the market and putting into service
          </p>
          <ul class="faq-subList faq-subList-number">
            <li class="faq-subList_item">
              <span>
                A device may be placed on the market or put into service only if
                it complies with this Regulation when duly supplied and properly
                installed, maintained and used in accordance with its intended
                purpose.
              </span>
            </li>
            <li class="faq-subList_item">
              <span>
                A device shall meet the general safety and performance
                requirements set out in Annex I which apply to it, taking into
                account its intended purpose.
              </span>
            </li>
            <li class="faq-subList_item">
              <span>
                Demonstration of conformity with the general safety and
                performance requirements shall include a performance evaluation
                in accordance with Article 56.
              </span>
            </li>
            <li class="faq-subList_item">
              <span>
                Devices that are manufactured and used within health
                institutions, with the exception of devices for performance
                studies, shall be considered as having been put into service.
              </span>
            </li>
            <li class="faq-subList_item">
              <span>
                With the exception of the relevant general safety and
                performance requirements set out in Annex I, the requirements of
                this Regulation shall not apply to devices manufactured and used
                only within health institutions established in the Union,
                provided that all of the following conditions are met:
                <ul class="faq-subList-childList_latin">
                  <li>
                    the devices are not transferred to another legal entity;
                  </li>
                  <li>
                    manufacture and use of the devices occur under appropriate
                    quality management systems;
                  </li>
                  <li>
                    the laboratory of the health institution is compliant with
                    standard EN ISO 15189 or where applicable national
                    provisions, including national provisions regarding
                    accreditation;
                  </li>
                  <li>
                    the health institution justifies in its documentation that
                    the target patient group's specific needs cannot be met, or
                    cannot be met at the appropriate level of performance by an
                    equivalent device available on the market;
                  </li>
                  <li>
                    the health institution provides information upon request on
                    the use of such devices to its competent authority, which
                    shall include a justification of their manufacturing,
                    modification and use;
                  </li>
                  <li>
                    the health institution draws up a declaration which it shall
                    make publicly available, including:
                    <ul>
                      <li>
                        the name and address of the manufacturing health
                        institution,
                      </li>
                      <li>the details necessary to identify the devices,</li>
                      <li>
                        a declaration that the devices meet the general safety
                        and performance requirements set out in Annex I to this
                        Regulation and, where applicable, information on which
                        requirements are not fully met with a reasoned
                        justification therefor;
                      </li>
                    </ul>
                  </li>
                  <li>
                    as regards class D devices in accordance with the rules set
                    out in Annex VIII, the health institution draws up
                    documentation that makes it possible to have an
                    understanding of the manufacturing facility, the
                    manufacturing process, the design and performance data of
                    the devices, including the intended purpose, and that is
                    sufficiently detailed to enable the competent authority to
                    ascertain that the general safety and performance
                    requirements set out in Annex I to this Regulation are met.
                    Member States may apply this provision also to class A, B or
                    C devices in accordance with the rules set out in Annex
                    VIII;
                  </li>
                  <li>
                    the health institution takes all necessary measures to
                    ensure that all devices are manufactured in accordance with
                    the documentation referred to in point
                  </li>
                  <li>
                    the health institution reviews experience gained from
                    clinical use of the devices and takes all necessary
                    corrective actions.
                  </li>
                  <p>
                    Member States may require that such health institutions
                    submit to the competent authority any further relevant
                    information about such devices which have been manufactured
                    and used on their territory. Member States shall retain the
                    right to restrict the manufacture and use of any specific
                    type of such devices and shall be permitted access to
                    inspect the activities of the health institutions.
                    <br />
                    This paragraph shall not apply to devices that are
                    manufactured on an industrial scale.
                  </p>
                </ul>
              </span>
            </li>
            <li class="faq-subList_item">
              In order to ensure the uniform application of Annex I, the
              Commission may adopt implementing acts to the extent necessary to
              resolve issues of divergent interpretation and of practical
              application. Those implementing acts shall be adopted in
              accordance with the examination procedure referred to in Article
              107(3).
            </li>
          </ul>
        </div>
        <hr />
      </li>
      <li class="faq-list_item">
        <div class="d-flex align-items-center">
          <span class="faq-list_item-index">28.</span>
          <h1 class="m-0 faq-list_item-question">
            What are the requirements of ISO 15189 for medical device
            laboratories?
          </h1>
        </div>
        <div>
          <p class="faq-list_item-answer">
            ISO 15189 is an international standard that specifies requirements
            for quality and competence in medical laboratories. The standard is
            designed to help laboratories develop a quality management system
            and demonstrate their competence to produce reliable results. The
            requirements of ISO 15189 cover various aspects of laboratory
            operations. The standard is divided into several sections, each
            addressing different elements of the quality management system. Here
            is an overview of the key requirements of ISO 15189:
          </p>
          <ul class="faq-subList faq-subList-number">
            <li class="faq-subList_item">
              <span
                ><strong
                  >Scope and Normative References (Clauses 1 and 2):</strong
                >
                <ul class="faq-subList-childList">
                  <li>
                    Defines the scope of the standard and refers to other
                    relevant documents.
                  </li>
                </ul>
              </span>
            </li>
            <li class="faq-subList_item">
              <span
                ><strong>Terms and Definitions (Clause 3):</strong>
                <ul class="faq-subList-childList">
                  <li>
                    Provides definitions of terms used throughout the standard.
                  </li>
                </ul>
              </span>
            </li>
            <li class="faq-subList_item">
              <span
                ><strong> Management Requirements (Clauses 4-7):</strong>
                <p class="faq-subList_item m-0">
                  3.1 Clause 4 - Management Requirements:
                </p>
                <ul class="faq-subList-childList">
                  <li>
                    Focuses on the overall management of the laboratory,
                    including the organization's commitment to quality, the
                    establishment and maintenance of a quality management
                    system, and documentation requirements.
                  </li>
                </ul>
                <p class="faq-subList_item m-0">
                  3.2 Clause 5 - Technical Requirements:
                </p>
                <ul class="faq-subList-childList">
                  <li>
                    Specifies technical competence requirements for the
                    laboratory, covering personnel, facilities, equipment, and
                    the pre-examination, examination, and post-examination
                    processes.
                  </li>
                </ul>
                <p class="faq-subList_item m-0">
                  3.3 Clause 6 - Accommodation and Environmental Conditions:
                </p>
                <ul class="faq-subList-childList">
                  <li>
                    Addresses the physical environment of the laboratory,
                    including requirements for facilities, safety, and
                    environmental conditions.
                  </li>
                </ul>
                <p class="faq-subList_item m-0">
                  3.4 Clause 7 - Ensuring the Quality of Test Results:
                </p>
                <ul class="faq-subList-childList">
                  <li>
                    Focuses on quality control, validation of examination
                    procedures, participation in proficiency testing, and the
                    management of critical and significant results.
                  </li>
                </ul>
                <p class="faq-subList_item m-0">
                  4. Examination Procedures (Clauses 8-9):
                </p>
                <p class="faq-subList_item m-0">4.1 Clause 8 - Examination:</p>
                <ul class="faq-subList-childList">
                  <li>
                    Details requirements related to the examination process,
                    including sample identification, handling, and processing.
                  </li>
                </ul>
                <p class="faq-subList_item m-0">
                  4.2 Clause 9 - Assuring the Quality of Examination Results:
                </p>
                <ul class="faq-subList-childList">
                  <li>
                    4.2 Clause 9 - Assuring the Quality of Examination Results:
                    Covers the verification and validation of examination
                    procedures, as well as the use of reference materials and
                    participation in interlaboratory comparison or proficiency
                    testing.
                  </li>
                </ul>
                <p class="faq-subList_item m-0">
                  5. Assuring the Quality of Test Results (Clauses 10-12):
                </p>
                <p class="faq-subList_item m-0">
                  5.1 Clause 10 - Reporting Results:
                </p>
                <ul class="faq-subList-childList">
                  <li>
                    Specifies requirements for the content and format of test
                    reports.
                  </li>
                </ul>
                <p class="faq-subList_item m-0">
                  5.2 Clause 11 - Release of Results:
                </p>
                <ul class="faq-subList-childList">
                  <li>
                    Addresses the release of examination results, including
                    communication with users and authorization of results.
                  </li>
                </ul>
                <p class="faq-subList_item m-0">
                  5.3 Clause 12 - Interpretation and Consultation:
                </p>
                <ul class="faq-subList-childList">
                  <li>
                    Covers the interpretation of results and the provision of
                    consultation services.
                  </li>
                </ul>

                <p class="faq-subList_item m-0">
                  6. Management System Requirements (Clauses 13-18):
                </p>
                <p class="faq-subList_item m-0">
                  6.1 Clause 13 - Laboratory Management:
                </p>
                <ul class="faq-subList-childList">
                  <li>
                    Addresses the overall management of the laboratory,
                    including management reviews and continual improvement.
                  </li>
                </ul>
                <p class="faq-subList_item m-0">
                  6.2 Clause 14 - Technical Management:
                </p>
                <ul class="faq-subList-childList">
                  <li>
                    Covers technical management aspects, including competence,
                    equipment, and measurement traceability.
                  </li>
                </ul>
                <p class="faq-subList_item m-0">
                  6.3 Clause 15 - Management Review:
                </p>
                <ul class="faq-subList-childList">
                  <li>
                    Requires regular reviews of the laboratory's management
                    system.
                  </li>
                </ul>
                <p class="faq-subList_item m-0">
                  6.4 Clause 16 - Continual Improvement:
                </p>
                <ul class="faq-subList-childList">
                  <li>
                    Focuses on the need for continual improvement in all aspects
                    of the laboratory's operations.
                  </li>
                </ul>
                <p class="faq-subList_item m-0">
                  6.5 Clause 17 - Corrective Action:
                </p>
                <ul class="faq-subList-childList">
                  <li>
                    Specifies requirements for corrective actions in response to
                    nonconformities.
                  </li>
                </ul>
                <p class="faq-subList_item m-0">
                  6.6 Clause 18 - Preventive Action:
                </p>
                <ul class="faq-subList-childList">
                  <li>
                    Addresses the implementation of preventive actions to avoid
                    potential issues.
                  </li>
                </ul>
                <p class="faq-subList_item m-0">7. Annexes:</p>
                <ul class="faq-subList-childList">
                  <li>
                    Provides additional guidance and information to support the
                    implementation of specific aspects of the standard.
                  </li>
                </ul>
              </span>
            </li>
          </ul>
        </div>
        <hr />
      </li>
      <li class="faq-list_item">
        <div class="d-flex align-items-center">
          <span class="faq-list_item-index">29.</span>
          <h1 class="m-0 faq-list_item-question">
            What are the steps required to convert Laboratory Developed Test
            (LDT) to In Vitro Diagnostic Test (IVD) by EU IVDR 746/2017
            regulations?
          </h1>
        </div>
        <div>
          <p class="faq-list_item-answer">
            As of January 2022, the European Union In Vitro Diagnostic
            Regulation (IVDR) 2017/746 had come into effect, replacing the
            previous In Vitro Diagnostic Directive (IVDD). The IVDR establishes
            new and more stringent requirements for the regulatory oversight of
            in vitro diagnostic (IVD) devices. If there have been changes or
            updates to the regulations since then, it's important to refer to
            the most recent guidance and regulations from the European Medicines
            Agency (EMA) and other relevant authorities.
            <br />
            Here are general steps that might be involved in transitioning a
            Laboratory Developed Test (LDT) to an In Vitro Diagnostic Test (IVD)
            in compliance with the EU IVDR:
          </p>
          <ul class="faq-subList faq-subList-number">
            <li class="faq-subList_item">
              <span
                ><strong>Device Classification:</strong>
                <ul class="faq-subList-childList">
                  <li>
                    Classify the IVD device according to the risk-based
                    classification system outlined in Annex VIII of the IVDR.
                    Determine whether the device is classified as Class A, B, C,
                    or D based on factors such as intended use and technological
                    characteristics.
                  </li>
                </ul>
              </span>
            </li>
            <li class="faq-subList_item">
              <span
                ><strong>Conduct Performance Evaluation:</strong>
                <ul class="faq-subList-childList">
                  <li>
                    Perform a performance evaluation of the IVD device in
                    accordance with the requirements specified in Annex XIII of
                    the IVDR. This involves assessing and documenting the
                    analytical and clinical performance of the device.
                  </li>
                </ul>
              </span>
            </li>
            <li class="faq-subList_item">
              <span
                ><strong>Quality Management System (QMS):</strong>
                <ul class="faq-subList-childList">
                  <li>
                    Establish and implement a Quality Management System (QMS) in
                    compliance with the requirements of the IVDR. The QMS should
                    cover various aspects, including design and development,
                    risk management, clinical evaluation, and post-market
                    surveillance.
                  </li>
                </ul>
              </span>
            </li>
            <li class="faq-subList_item">
              <span
                ><strong>Technical Documentation:</strong>
                <ul class="faq-subList-childList">
                  <li>
                    Prepare and compile the technical documentation required for
                    CE marking. This documentation should include information on
                    the design, performance, and safety of the IVD device. It
                    should also cover aspects such as the results of the
                    performance evaluation and clinical evaluation.
                  </li>
                </ul>
              </span>
            </li>
            <li class="faq-subList_item">
              <span
                ><strong>Conformity Assessment:</strong>
                <ul class="faq-subList-childList">
                  <li>
                    Engage a Notified Body to perform the conformity assessment
                    for the IVD device. The Notified Body will assess the
                    technical documentation, conduct audits (if necessary), and
                    issue a Certificate of Conformity if the device meets the
                    requirements of the IVDR.
                  </li>
                </ul>
              </span>
            </li>
            <li class="faq-subList_item">
              <span
                ><strong>Labeling and Instructions for Use:</strong>
                <ul class="faq-subList-childList">
                  <li>
                    Ensure that the labeling and instructions for use comply
                    with the requirements of the IVDR. This includes providing
                    clear and accurate information for users, healthcare
                    professionals, and patients.
                  </li>
                </ul>
              </span>
            </li>
            <li class="faq-subList_item">
              <span
                ><strong>Post-Market Surveillance:</strong>
                <ul class="faq-subList-childList">
                  <li>
                    Implement a post-market surveillance system to monitor the
                    performance and safety of the IVD device once it is placed
                    on the market. This involves collecting and analyzing data
                    on the device's performance, as well as reporting adverse
                    events.
                  </li>
                </ul>
              </span>
            </li>
            <li class="faq-subList_item">
              <span
                ><strong>Registration with Competent Authorities:</strong>
                <ul class="faq-subList-childList">
                  <li>
                    Register the IVD device with the competent authorities of
                    the EU Member States where the device will be placed on the
                    market. This registration may involve submitting information
                    about the device, the manufacturer, and other relevant
                    details.
                  </li>
                </ul>
              </span>
            </li>
          </ul>
          <p class="faq-list_item-answer">
            It's important to note that the transition from an LDT to an IVD
            under the EU IVDR involves significant regulatory requirements and
            compliance efforts. Manufacturers should seek professional
            regulatory advice, keep abreast of any updates to the regulatory
            landscape, and work closely with Notified Bodies to ensure
            compliance with the IVDR.
          </p>
        </div>
        <hr />
      </li>
    </ul>
  </div>
</div>
